Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of [14C] Lomedeucitinib in healthy male participants
NCT06088264Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lomedeucitinib in psoriasis, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration at Day 17, Area under the concentration-time curve extrapolated to infinite time at Day 17 and 10 more. Started Oct 2023; status: completed.
02
Drugs
lomedeucitinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06088264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088264.